Zidovudine and interferon-α treatment induces a high response rate and reduces HTLV-1 proviral load and VEGF plasma levels in patients with adult T-cell leukemia from North East Iran

Leukemia and Lymphoma

Volumn 48, Issue 2, 2007, Pages 330-336

  Kchour, Ghada ^a   Makhoul, Nadine ^b   Mahmoudi, Mahmoud ^a   Kooshyar, Mohamad Mehdi ^c   Shirdel, Abbas ^c   Rastin, Maryam ^a   Rafatpanah, Houshang ^a   Tarhini, Mahdi ^a   Zalloua, Pierre ^b   Hermine, Olivier ^d   Farid, Reza ^a   Bazarbachi, Ali ^b  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; VASCULOTROPIN; VINCRISTINE; ZIDOVUDINE; ANTIVIRUS AGENT; UNCLASSIFIED DRUG; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FEVER; DRUG RESPONSE; DYSPEPSIA; EDEMA; FEMALE; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; IRAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIDE EFFECT; SURVIVAL TIME; T CELL LEUKEMIA; VIRUS CARRIER; VIRUS LOAD; WEIGHT REDUCTION; BLOOD; DRUG COMBINATION; DRUG EFFECT; HUMAN T CELL LEUKEMIA VIRUS INFECTION; ISOLATION AND PURIFICATION; MIDDLE AGED; PROVIRUS; T CELL LYMPHOMA; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HTLV-I INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; INTERFERON-ALPHA; IRAN; LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED; MALE; MIDDLE AGED; PROVIRUSES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VIRAL LOAD; ZIDOVUDINE;

EID: 34247892540     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190601071717     Document Type: Article

References (29)

1. Hinuma, Y., Komoda, H., Chosa, T., Kondo, T., Kohakura, M. and Takenaka, T. (1982) Antibodies to adult T-cell associated-virus-associated antigen (ATLA) in sera from patients with ATL and controls in Japan: A nation-wide sero-epidemiologic study. Int J Cancer, 29, pp. 631-635.
2. Gessain, A., Barin, F., Vernant, J. C., Gout, O., Maurs, L. and Calender, A. (1985) Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet, 2, pp. 407-410.
3. Takatsuki, F., Yamaguchi, K. and Hattori, T. (1990) Adult T-cell leukemia/lymphoma. Retrovirus Biology and Human Disease, pp. 147-159. Marcel Deker, New York
4. Kaplan, J. and Khabbaz, R. (1993) The epidemiology of human T-lymphotropic virus type I and II. Med Virol, 3, pp. 137-148.
5. Gessain, A. (1996) Epidemiology of HTLV-I and associated diseases. Human T-Cell Lymphotropic Virus Type 1, pp. 33-64. Willey, Chichester
6. Safai, B., Huang, J. L., Boeri, E., Farid, R., Raafat, J. and Schutzer, P. (1996) Prevalence of HTLV type I infection in Iran: A serological and genetic study. AIDS Res Hum Retroviruses, 12, pp. 1185-1190.
7. Abbaszadegan, M. R., Gholamin, M., Tabatabaee, A., Farid, R., Houshmand, M. and Abbaszadegan, M. (2003) Prevalence of human T-lymphotropic virus type 1 among blood donors from Mashhad. Iran J Clin Microbiol, 41, pp. 2593-2595.
8. Bazarbachi, A., Ghez, D., Lepelletier, Y., Nasr, R., de The, H. and El-Sabban, M. E. (2004) New therapeutic approaches for adult T-cell leukaemia. Lancet Oncol, 5, pp. 664-672.
9. Shimoyama, M. (1992) Treatment of patients with adult T-cell lymphoma-lymphoma: An overview. Advances in Adult T-Cell Leukaemia and HTLV-I Research, Vol. 39, pp. 43-56. Japan Scientific Societies Press, Tokyo
10. Yamada, Y., Tomonaga, M., Fukuda, H., Hanada, S., Utsunomiya, A. and Tara, M. (2001) A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol, 113, pp. 375-382.
11. Hermine, O., Bouscary, D., Gessain, A., Turlure, P., LeBlond, V. and Franck, N. (1995) Treatment of HTLV-I associated adult T-cell lymphoma-lymphoma with a combination of zidovudine and α-interferon. N Engl J Med, 332, pp. 1749-1751.
12. Gill, P., Harrington, W., Kaplan, M., Ribeiro, R. C., Bennett, J. M. and Liebman, H. A. (1995) Treatment of adult T-cell lymphoma-lymphoma with a combination of interferon-α and zidovudine. N Engl J Med, 332, pp. 1744-1748.
13. Bazarbachi, A. and Hermine, O. (1996) Treatment by a combination of zidovudine and α-interferon in naive and pretreated Adult T-cell lymphoma/lymphoma patients. J Acquir Immune Defic Syndr Hum Retrovirol, 13, pp. S186-S190.
14. Hermine, O., Allard, I., Lévy, V., Arnulf, B., Gessain, A. and Bazarbachi, A. (2002) For the French ATL therapy group. A prospective phase II clinical trial with the use of zidovudine and interferon-α in the acute and lymphoma forms of adult T-cell lymphoma/lymphoma. Hematol J, 3, pp. 276-282.
15. Folkman, J. (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol, 29, pp. 15-18.
16. El-Sabban, M., Abu, Merhi R., Abi, Haidar H., Arnulf, B., Basbous, J. and Khoury, H. (2002) Human T-cell lymphotropic virus type I transformed cells induce angiogenesis and establish functional gap junctions with endothelial cells. Blood, 99, pp. 3383-3389.
17. Bazarbachi, A., Merhi, R. A., Gessain, A., Talhouk, R., El-Khoury, H. and Nasr, R. (2004) Human T-cell lymphotropic virus type I-infected cells extravasate through the endothelial barrier by a local angiogenesis-like mechanism. Cancer Res, 64, pp. 2039-2046.
18. Shimoyama, M. (1991) Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-1987). Br J Haematol, 79, pp. 428-437.
19. Okayama, A., Stuver, S., Matsuoka, M., Ishizaki, J., Tanaka, G. and Kubuki, Y. (2004) Role of HTLV-1 proviral DNA load and clonality in the development of adult T-cell leukemia/lymphoma in asymptomatic carriers. Int J Cancer, 110, pp. 621-625.
20. Hayashibara, T., Yamada, Y., Miyanishi, T., Mori, H., Joh, T. and Maeda, T. (2001) Vascular endothelial growth factor and cellular chemotaxis: A possible autocrine pathway in adult T-cell leukemia cell invasion. Clin Cancer Res, 7, pp. 2719-2726.
21. Kamihira, S., Dateki, N., Sugahara, K., Hayashi, T., Harasawa, H. and Minami, S. (2003) Significance of HTLV-1 proviral load quantification by real-time PCR as a surrogate marker for HTLV-1-infected cell count. Clin Lab Haematol, 25, pp. 111-117.
22. Taylor, G. P., Hall, S. E., Navarrete, S., Michie, C. A., Davis, R. and Witkover, A. D. (1999) Effect of lamivudine on human T-cell leukemia virus type 1 (HTLV-1) DNA copy number, T-cell phenotype, and anti-tax cytotoxic T-cell frequency in patients with HTLV-1-associated myelopathy. J Virol, 73, pp. 10289-10295.
23. Machuca, A. and Soriano, V. (2000) In vivo fluctuation of HTLV-I and HTLV-II proviral load in patients receiving antiretroviral drugs. J Acquir Immune Defic Syndr, 24, pp. 189-193.
24. Bazarbachi, A., Nasr, R., El-Sabban, M. E., Mahe, A., Mahieux, R. and Gessain, A. (2000) Evidence against a direct cytotoxic effect of α-interferon and zidovudine in HTLV-I associated adult T cell lymphoma/lymphoma. Leukaemia, 14, pp. 716-721.
25. Macchi, B., Faraoni, I., Zhang, J., Grelli, S., Favalli, C. and Mastino, A. (1997) AZT inhibits the transmission of human T cell leukaemia/ lymphoma virus type I to adult peripheral blood mononuclear cells in vitro. J Gen Virol, 78, pp. 1007-1016.
26. Isono, T., Ogawa, K. and Seto, A. (1990) Antiviral effect of zidovudine in the experimental model of adult T cell leukaemia in rabbits. Leuk Res, 14, pp. 841-847.
27. Oguma, S., Imamura, Y. and Kusumoto, Y. (1992) Accelerated declining tendency of human T-cell leukaemia virus type I carrier rates among younger blood donnors in Kumamoto, Japan. Cancer Res, 52, pp. 2620-2626.
28. Feng, X., Heyden, N. V. and Ratner, L. (2003) α-Interferon inhibits human T-cell leukaemia virus type 1 assembly by preventing Gag interaction with rafts. J Virol, 77, pp. 13389-13395.
29. Datta, A., Bellon, M., Sinha-Datta, U., Bazarbachi, A., Lepelletier, Y. and Canioni, D. (2006) Persistent inhibition of telomerase reprograms adult T-cell leukaemia to p53-dependent senescence. Blood, 108, pp. 1021-1029.